Randomized Phase II Trial of First-Line Treatment With Tailored Irinotecan and S-1 Therapy Versus S-1 Monotherapy for Advanced or Recurrent Gastric Carcinoma (JFMC31-0301)

Anti-Cancer Drugs - United States
doi 10.1097/cad.0b013e328345b509
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Ovid Technologies (Wolters Kluwer Health)

Related search

Multicenter Phase II Study of Oxaliplatin, Irinotecan, and S-1 as First-Line Treatment for Patients With Recurrent or Metastatic Biliary Tract Cancer

Cancer Research and Treatment
Cancer ResearchOncology
2018English

Combination Therapy With Docetaxel and S-1 as a First-Line Treatment in Patients With Advanced or Recurrent Gastric Cancer: A Retrospective Analysis

World Journal of Surgical Oncology
SurgeryOncology
2010English

Irinotecan Monotherapy as Third-Line or Later Treatment in Advanced Gastric Cancer

Gastric Cancer
Cancer ResearchMedicineOncologyGastroenterology
2017English

Phase I/Ii Study of S-1 Combined With Paclitaxel in Patients With Unresectable and/or Recurrent Advanced Gastric Cancer

British Journal of Cancer
Cancer ResearchOncology
2006English

Multicenter Phase II Trial of Preoperative Chemoradiotherapy With S-1 for Locally Advanced Oral Squamous Cell Carcinoma

Cancer Chemotherapy and Pharmacology
Cancer ResearchToxicologyOncologyPharmacology
2013English

P2.01-005 a Randomized Phase II Trial of Erlotinib vs S-1 in Patients With NSCLC as Third- Or Fourth-Line Therapy (HOT1002)

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2017English

Phase II Study on the Combination of Irinotecan Plus Cisplatin as a Second-Line Therapy in Patients With Advanced or Recurrent Gastric Cancer

Molecular and Clinical Oncology
Cancer ResearchOncology
2013English

Safety and Continuity of Second- And Third-Line Therapy With Paclitaxel or Irinotecan for Advanced and Recurrent Gastric Cancer

Molecular and Clinical Oncology
Cancer ResearchOncology
2014English

P-161 * a Phase I-Trial Assessing Several Schedules of Oral S-1 Combined With Fixed Doses of Oxaliplatin and Irinotecan in Patients With Advanced or Metastatic Digestive Adenocarcinoma as First- Or Second-Line Treatment

Annals of Oncology
MedicineOncologyHematology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy